Randomized Controlled Trial Examining the Ripple Effect of a Nationally Available Weight Management Program on Untreated Spouses
Researchers have found that when one member of a couple commits to losing weight, the chances are good their partner…
Results Show 14.7% Total Body Weight Loss at Twelve Months ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical…
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018.
According to the first study to quantify the proportion of cancers attributable to diabetes and high BMI published in The Lancet Diabetes & Endocrinology, diabetes and high BMI over 25 kg/m2 were the cause of 5.6 percent of new cancer cases worldwide.
ReShape Lifesciences Inc. announced today that their ReShape Integrated Dual Balloon technology has been granted employee coverage through a supplemental coverage policy at a multinational telecommunications corporation that provides mobile telephone, fixed telephone and broadband subscription television services.